Safety and immunogenicity of SARS-CoV-2 mRNA vaccine booster doses in kidney transplant recipients: results of a 12-mo follow-up from a prospective observational study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084813" target="_blank" >RIV/00023001:_____/24:00084813 - isvavai.cz</a>

Result on the web

<a href="https://journals.lww.com/transplantationdirect/fulltext/2024/06000/safety_and_immunogenicity_of_sars_cov_2_mrna.19.aspx" target="_blank" >https://journals.lww.com/transplantationdirect/fulltext/2024/06000/safety_and_immunogenicity_of_sars_cov_2_mrna.19.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/TXD.0000000000001645" target="_blank" >10.1097/TXD.0000000000001645</a>

Result language

angličtina

Original language name

Safety and immunogenicity of SARS-CoV-2 mRNA vaccine booster doses in kidney transplant recipients: results of a 12-mo follow-up from a prospective observational study

Original language description

Background.Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs.Methods.A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology.Results.Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [e beta] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (e beta 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (e beta 1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19.Conclusions.Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

<a href="/en/project/NU22-C-126" target="_blank" >NU22-C-126: Aspects of immune response and efficacy of booster dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Transplantation Direct

ISSN

2373-8731

e-ISSN

2373-8731

Volume of the periodical

10

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

"art. no. E1645"

UT code for WoS article

001226398300001

EID of the result in the Scopus database

2-s2.0-85193939846